Small-Cap Biotech Poised for a Quick Double-Digit Pop

StreetAuthority Network

When it comes to investing in young and unproven biotech stocks, you want to look for a few key characteristics. First, the company should be targeting a market for which current treatments are less than ideal. Second, this potential market should be fairly large in size and scope. And third, you want to focus on companies that have already established compelling, robust results in clinical testing trials.

New Jersey-based Insmed (INSM) checks all those boxes. Better still, a clear imminent catalyst exists to send this stock to fresh highs. With a market cap of roughly $350 million, Insmed qualifies as a small cap, but it is hardly a well-kept secret. But with a few good breaks on the regulatory front, this company's market value could easily -- and quickly -- tack on millions more. Notably, the stock has slumped more than 20% since hitting a new 52-week high in late May, providing a fresh entry point.

Clearing the Passageways

Insmed has developed Arikace, which is an inhalable antibiotic that brings medicine right to areas where lungs are infected. Arikace is currently in Phase III trials for patients with cystic fibrosis (CF), and in Phase II for patients with non-tuberculosis mycobacteria (NTM) lung infections.

The patented eFlow Electronic Nebulizer is a hand-held device that allows patients to easily inhale the drug amikacin, which is already approved and effective, and therefore unlikely to raise safety concerns with the FDA. In fact, thus far in clinical testing, patients using Arikace have experienced no notable side effects.

The distinction here is Arikace's fast-acting and accurate form of delivery. Another drug, Tobramycin, also utilizes amikacin, but a formulation developed by Novartis (NVS) has proven to have limited efficacy and sometimes must be taken several times a day by the patient to ensure that the drug is delivered. In contrast, Arikace is formulated to penetrate into the infection, and not merely reside on its surface, thanks to a unique system of layered lipids surrounding amikacin.

Although cystic fibrosis treatments exist, Insmed has a chance to take significant market share if Arikace is approved. That market is roughly $400 million annually. Yet it's the other indication, for NTM lung infections, that you also need to track, as there are currently no solutions on the market to treat this ailment. Every year, 50,000 new cases of NTM lung infection are diagnosed, and patients often suffer recurrences that can eventually be fatal. Look for top-line data on this Phase II testing by the end of 2013.

In a bid to accelerate its approval, the FDA recently gave Arikace "orphan drug" status for NTM infections. (The company hopes to get a similar designation in the EU.) Orphan drug designation provides certain exclusivity benefits, tax credits for research and a waiver of the New Drug Application user fee.

Looking at just these two indications (CF and NTM lung infections), Insmed may be looking at $600 million in annual revenues by 2020, according to analysts at Lazard Capital, who gave the stock a $20 price target.

Upcoming CF Data

Circling back to the Phase III tests for the treatment of cystic fibrosis, investors are expecting Insmed to release preliminary data at some point in the next few weeks.

"It is our intention to release the complete dataset at a scientific or medial conference and hope to have it published in a peer review journal," noted company President Will Lewis on a call with analysts in early May.

If the CF data are as positive as many suspect, then this stock should get an instant pop to the upper teens. A move to $18 represents almost 60% upside from current levels, and looking beyond this catalyst, further upside surely remains.

Analysts generally have price targets in the upper teens and low $20s, though that price accommodates for the possibility of an FDA rejection.

For example, UBS analyst Matthew Harrison gave the stock a slightly lower $17.50 price target, but said, "We see a positive CF study as the major catalyst with positive data potentially pushing the stock into the $20s." More specifically, Harrison said he sees this stock going to $25 if "both the CF and NTM trials are positive; and NTM is able to achieve early approval."

Recommended Trade Setup:

-- Buy INSM up to $13
-- Set stop-loss at $10
-- Set initial price target at $18 for a potential 38% gain in three months

Related Articles

Rates

View Comments (0)

Recommended for You

  • Tycoon buys 30 Rolls-Royces for Macau hotel

    A Hong Kong tycoon has placed the biggest ever order for Rolls-Royce cars, agreeing to buy 30 Phantoms to chauffeur guests at a luxury resort he's building in the global gambling capital of Macau. Stephen Hung's $20 million purchase surpasses the 14 Phantoms bought by Hong Kong's Peninsula Hotel in…

    Associated Press
  • Enjoy this refreshing Triple Play offer!

    Get FIOS TV Mundo starting at $79.99/mo. w/ no annual contract + 2-yr. price guarantee. Or sign for 2 yrs. & get a $300 prepaid Visa. Click here.

    AdChoicesVerizon FiOS ®Sponsored
  • Tycoon's arrest sends shock wave through Russia

    Tycoon's arrest sends shock wave through Russia MOSCOW (AP) — The arrest of a Russian telecoms and oil tycoon has sent shock waves through the country's business community, with some fearing a return to the dark days of a decade ago, when the Kremlin asserted its power by imprisoning the country's…

    Associated Press
  • Before You Buy Alibaba, Check Out 4 Top China Stocks

    Before You Buy Alibaba, Check Out 4 Top China Stocks While investors gear up for Alibaba Group 's (BABA) hotly anticipated initial public offering, don't forget about other Chinese stocks that are worth keeping an eye on. Today's Young Guns Screen of

    Investor's Business Daily
  • As Fed takes baby steps, Cramer's trick for profit

    In turn, Cramer says making money in the market, involves looking at the environment through the lens of the Fed. "The trick is to remember that they speak for the common person," Cramer said. "The Fed wants the common person to make money." With that backdrop always in mind, Cramer says it becomes…

    CNBC
  • Play

    Citi, Bank of America Offer Discounted Mortgages

    Citigroup and Bank of America will offer mortgages at discounted interest rates to help borrowers with low incomes or subprime credit. AnnaMaria Andriotis joins MoneyBeat. Photo: Getty.

    WSJ Live
  • Costco Stores in Canada to Stop Taking American Express

    “The credit card relationship between American Express and Costco Wholesale Canada will not be renewed when it expires” on Dec. 31, the company said today in an e-mail to Canadian customers. The message was attributed to Lorelle Gilpin, vice president of marketing and membership for Costco…

    Bloomberg
  • "The Retiree Next Door": How successful retirees stretch their savings

    "The Retiree Next Door": How successful retirees stretch their savingsBy the time she hit her late 40s, Toni Eugenia wasn’t sure she would ever be able to retire. Eugenia, 56, a pharmacy technician who lived in Houston, was nearly $200,000 in debt and

    Yahoo Finance
  • 1 Tip To Lose Belly Fat

    It's Hollywood's Hottest Diet And Gets Rid Of Stubborn Fat Areas Like Nothing Else.

    AdChoicesagoodcooksSponsored
  • CNBC Anchor Calls Out Fed-Hater Bill Fleckenstein In Startling Shouting Match

    CNBC Bill Fleckenstein of Fleckenstein Capital appeared on CNBC's Futures Now program on Tuesday. Futures Now host Jackie DeAngelis came out swinging, asking Fleckenstein right at the top if he was willing to admit that he had misunderstood monetary policy. Sounding taken aback, Fleckenstein…

    Business Insider
  • Beanie Babies creator's sentence debated in court

    Beanie Babies creator's sentence debated in court CHICAGO (AP) — Federal prosecutors seeking to put the billionaire creator of Beanie Babies in prison for hiding millions in Swiss bank accounts told appellate court judges Wednesday that the toymaker's sentence of probation threatens to erode the…

    Associated Press
  • Apple to unveil new iPads, operating system on Oct. 21 : report

    The company plans to unveil the sixth generation of its iPad and the third edition of the iPad mini, as well as its operating system OS X Yosemite, which has undergone a complete visual overhaul, the Internet news website said. Trudy Muller, a spokeswoman for Apple, declined to comment. The iPad is…

    Reuters
  • Margaritaville casino owners seek bankruptcy

    The owner of Biloxi's Margaritaville casino has filed for Chapter 11 bankruptcy protection Tuesday, only hours before a hearing where the landlord aimed to seize the property. The filing by MVB Holding LLC in U.S. Don Dornan, a lawyer for landlord Clay Point LLC, said the company had planned to ask…

    Associated Press
  • Embraer to sell 50 E-175 jets to Republic in $2.1 billion deal

    Brazil's Embraer SA, the world's third largest commercial planemaker, said on Wednesday it booked a firm order from U.S. The deal, which will be included in Embraer's order book for the third quarter, is valued at $2.1 billion, the planemaker said in a securities filing. The planes will be operated…

    Reuters
  • Play

    What the Fed Meeting Means for Bonds

    Janet Yellen & Co. are expected to hint at their timetable for raising interest rates. Here's how investors should prepare ahead of the meeting.

    WSJ Live
  • Accomplish your career goals

    At Capella University, you can learn the skills you need to succeed. Why wait another day? Get started today.

    AdChoicesCapella UniversitySponsored
  • Gilead Stock Is Falling On These Drug Setbacks

    Gilead Stock Is Falling On These Drug Setbacks Gilead Sciences (GILD) shares are backsliding Wednesday on news that the patient drop-out rate for hepatitis C drug Sovaldi is quadruple that of clinical trials. In addition, the biotech's Phase 2 study results

    Investor's Business Daily
  • Here's What Mark Cuban Wishes He Knew About Money In His 20s

    Cuban is the owner of the Dallas Mavericks basketball team. Billionaire investor and entrepreneur Mark Cuban is generous with his advice. When we asked him what he wishes he'd known about money in his 20s, he said:

    Business Insider
  • Don't buy Alibaba stock: 'Dean of Valuation'

    Investors should steer clear of Alibaba , valuation expert Aswath Damodaran said Wednesday. On CNBC's " Fast Money ," Damodaran, a professor of finance at New York University's Stern School of Business, noted that he was looking at Alibaba stock from the perspective of a long-term investor, not a…

    CNBC
  • SHOE COMPANY: Our CEO Just Disappeared And Most Of The Money Is Gone

    "and like that: he's gone." This is an actual headline from a company press release: "CEO and COO disappeared, most of the company's cash missing." (Via FastFT) In a statement, German-based shoe company Ultrasonic said its CFO,  Chi Kwong Clifford Chan, has been unable to reach the company's CEO,…

    Business Insider
  • 10 rock-solid stocks for conservative investors

    10 rock-solid stocks for conservative investors Shares with low volatility can beat their indexes with less risk Bloomberg News/Landov U.S. Bancorp is the cheapest S&P 500 stock

    MarketWatch
  • Billionaire Investor Says Chinese People Work Harder And Western Companies Could Face Deep Trouble After Alibaba IPO

    Michael Moritz, the chairman of VC firm Sequoia Capital, is a huge fan of Chinese internet companies and reiterated his enthusiasm for the Chinese market in an interview with The Wall Street Journal Wednesday. The billionaire investor described the Alibaba IPO as a “major landmark event” that is as…

    Business Insider
  • Norwich Information Security MS

    Online, accredited, top ranked. NSA Center of Academic Excellence. Recognized by the Department of Homeland Security. Download your free brochure!

    AdChoicesNorwich UniversitySponsored
  • Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More

    Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More Stocks were firm on Wednesday morning ahead of the FOMC meeting outcome. Tuesday’s rally may have sparked higher interest again, and investors are looking for bargains

    24/7 Wall St.